| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.3 |
| mRNA | Pazopanib | FIMM | pan-cancer | AAC | -0.3 | 0.3 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.053 | 0.3 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.3 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.047 | 0.3 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |